[Profound survival benefit with concurrent chemotherapy: insights from a Chinese phase III trial in older patients with esophageal cancer].
作者信息
Schweizer Claudia, Fietkau Rainer, Putz Florian
机构信息
Strahlenklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstr. 27, 91054, Erlangen, Deutschland.
出版信息
Strahlenther Onkol. 2022 May;198(5):500-502. doi: 10.1007/s00066-022-01921-6. Epub 2022 Mar 14.
Abstract
摘要
相似文献
1
[Profound survival benefit with concurrent chemotherapy: insights from a Chinese phase III trial in older patients with esophageal cancer].[同步化疗带来显著生存获益：中国老年食管癌患者III期试验的见解]
Strahlenther Onkol. 2022 May;198(5):500-502. doi: 10.1007/s00066-022-01921-6. Epub 2022 Mar 14.
2
Consolidation chemotherapy after definitive concurrent chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma: a multicenter non-inferiority phase III randomized clinical trial.不可切除食管鳞癌患者根治性放化疗后巩固化疗：多中心非劣效性 III 期随机临床试验。
BMC Cancer. 2024 Mar 7;24(1):321. doi: 10.1186/s12885-024-12002-5.
3
A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.多中心前瞻性 III 期临床随机研究：同步整合加量调强放疗联合或不联合同期化疗治疗食管癌：3JECROG P-02 研究方案。
BMC Cancer. 2020 Sep 22;20(1):901. doi: 10.1186/s12885-020-07387-y.
4
The significance of consolidation chemotherapy after concurrent chemoradiotherapy in esophageal squamous cell carcinoma: a randomized controlled phase III clinical trial.同步放化疗后巩固化疗在食管鳞状细胞癌中的意义：一项随机对照III期临床试验
Thorac Cancer. 2024 Oct;15(28):2038-2048. doi: 10.1111/1759-7714.15424. Epub 2024 Aug 28.
5
Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.单药与双药同步放化疗治疗不可切除食管鳞癌的临床疗效比较：一项多中心回顾性分析。
Radiat Oncol. 2018 Jan 22;13(1):12. doi: 10.1186/s13014-018-0958-5.
6
Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.单药与双药化疗联合放化疗治疗食管鳞癌的前瞻性、随机、多中心 II 期临床试验。
Oncologist. 2020 Dec;25(12):e1900-e1908. doi: 10.1634/theoncologist.2020-0808. Epub 2020 Sep 28.
7
A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.一项 II/III 期随机对照临床试验，比较了手术后辅助放疗或同期放化疗与单纯手术治疗 IIB/III 期食管鳞癌患者的效果。
BMC Cancer. 2020 Feb 18;20(1):130. doi: 10.1186/s12885-020-6592-2.
8
Is Concurrent Chemotherapy With Radiotherapy for Esophageal Cancer Beneficial in Patients Aged 80 Years or Older?80 岁或以上食管癌患者同步放化疗是否有益？
Anticancer Res. 2019 Aug;39(8):4279-4283. doi: 10.21873/anticanres.13592.
9
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial.替吉奥胶囊同步放化疗对比单纯放疗治疗老年食管癌患者的疗效：一项多中心随机 3 期临床试验。
JAMA Oncol. 2021 Oct 1;7(10):1459-1466. doi: 10.1001/jamaoncol.2021.2705.
10
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.同步放化疗后行食管癌切除术可改善临床II期或III期食管癌患者的局部区域控制。
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1484-93. doi: 10.1016/j.ijrobp.2004.05.056.
本文引用的文献
1
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial.替吉奥胶囊同步放化疗对比单纯放疗治疗老年食管癌患者的疗效：一项多中心随机 3 期临床试验。
JAMA Oncol. 2021 Oct 1;7(10):1459-1466. doi: 10.1001/jamaoncol.2021.2705.
2
Impact of F-FDG-PET/CT on the identification of regional lymph node metastases and delineation of the primary tumor in esophageal squamous cell carcinoma patients.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对食管鳞癌患者区域淋巴结转移的识别和原发肿瘤的描绘的影响。
Strahlenther Onkol. 2020 Sep;196(9):787-794. doi: 10.1007/s00066-020-01630-y. Epub 2020 May 19.
3
Radiotherapy of the oldest old-feasibility and institutional analysis.高龄患者的放射治疗：可行性和机构分析。
Strahlenther Onkol. 2020 Aug;196(8):683-690. doi: 10.1007/s00066-020-01621-z. Epub 2020 May 4.
4
Does chemoradiotherapy benefit elderly patients with esophageal squamous cell cancer? A propensity-score matched analysis on multicenter data (3JECROG R-03A).放化疗对老年食管鳞癌患者有益吗？一项基于多中心数据（3JECROG R-03A）的倾向评分匹配分析。
BMC Cancer. 2020 Jan 15;20(1):36. doi: 10.1186/s12885-019-6461-z.
5
Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival.荷兰老年潜在可治愈性食管癌患者的确定性放化疗或手术：基于人群的全国性研究，涉及治疗模式和生存情况。
Acta Oncol. 2018 Sep;57(9):1192-1200. doi: 10.1080/0284186X.2018.1450521. Epub 2018 Mar 12.
6
Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.老年局部晚期食管癌患者的治疗利用情况及结局：美国国立癌症数据库综述
Cancer Med. 2017 Dec;6(12):2886-2896. doi: 10.1002/cam4.1250. Epub 2017 Nov 15.
7
A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer.一项针对老年食管癌患者的S-1同步放疗II期研究。
Oncotarget. 2017 Sep 15;8(47):83022-83029. doi: 10.18632/oncotarget.20938. eCollection 2017 Oct 10.
8
A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer.一项针对老年食管癌患者的S-1同步放疗的I期剂量递增研究。
J Thorac Dis. 2016 Mar;8(3):451-8. doi: 10.21037/jtd.2016.02.70.
9
Preoperative chemoradiotherapy for esophageal or junctional cancer.术前放化疗治疗食管或食管胃交界癌。
N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.
10
Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies.替吉奥（S-1）与顺铂联合用于治疗成人晚期胃癌时已获批准：与其他基于氟嘧啶的疗法的比较综述。
Onco Targets Ther. 2011;4:193-201. doi: 10.2147/OTT.S19059. Epub 2011 Nov 15.
Zotero 插件